Garwood Medical Devices Concludes its Third Round of Funding (Raised an Additional $4M)

Garwood Medical Devices, LLC, an emerging Buffalo-based company developing groundbreaking BioPrax™ technology to treat antibiotic-resistant bacterial biofilm infections associated with metallic orthopaedic implants, announced today its Series C round of accredited-investor funding has closed at $4 million, as projected.

The third round of financing, which began last September, attracted institutional investment from groups such as The WNY Impact Investment Fund and the Murray family, former owners of UC Coatings, along with global investors in the orthopaedics/health care space.

Garwood Medical has now raised $11.4 million, including $3.8 million in the Series B round, which closed October 2019 and was over-subscribed by $800,000. The company raised an initial $3.6 million during the company’s Series A financing round, which closed in September 2016. Funds raised will continue to support pre-clinical testing.

“We are very pleased with this continued success in raising much-needed capital and attracting interested partners,” said Wayne Bacon, president & CEO of Garwood Medical. “Our enthusiasm is further bolstered by the fact that 90 percent of our A- and B-round investors reinvested, taking 60 percent of the C round.”

Bacon said the three rounds of funding have been supported by individuals, including many orthopaedic surgeons and medical professionals, who understand the tremendous promise and value proposition the company provides.

Garwood Medical’s BioPrax™ device is currently under investigation to study the elimination of biofilm infections on prosthetic knee implants during early intervention procedures and used alongside the current standard of care.

BioPrax™ was accepted into the FDA’s Breakthrough Device Program in October 2019, an important milestone on the path to market acceptance and widespread usage among orthopaedic surgeons and hospitals, anticipated in 2025.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Noze states the grant will fund a groundbreaking clinical study aimed at detecting TB in high-burden countries, using the company's DiagNoze® — a handheld breathalyzer designed for the real-time detection and screening of various medical conditions, including infectious diseases such as TB.
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes.
The series B funding round saw participation from venture capital firms Blume Ventures, Steadview Capital, Nexus Venture Partners, Alpha Wave and Zomato founder Deepinder Goyal. Ultrahuman will deploy the funds towards building further manufacturing capacity and deeper research in the health tracking space notes Ultrahuman.
Bone Health Technologies Bone Health Technologies (BHT), a health technology innovator developing breakthrough non-invasive solutions for bone health, today announced the company has raised a...
Howard Robin, President and Chief Executive Officer of Nektar Therapeutics: "We are pleased to bring on TCGX as a new high-quality, long-term investor in Nektar as we advance rezpegaldesleukin through our Phase 2b studies in atopic dermatitis and alopecia areata. We are on track to report topline data from these studies in the first half of 2025, which will represent significant inflection points for Nektar. Today's financing further bolsters our financial position and extends the company's cash runway well into the third quarter of 2026."

By using this website you agree to accept Medical Device News Magazine Privacy Policy

Exit mobile version